Raymond James analyst Martin Auster assumed coverage of BridgeBio (BBIO) with an Outperform rating and a price target of $56, down from $57. Year-to-date outperformance in the stock price can be attributed to enthusiasm for the launch of Attruby in ATTR-CM and “strong early demand metrics,” the analyst tells investors. While shares have “run significantly,” the firm sees potential for incremental upside with more upward revisions to consensus in coming quarters, the analyst added.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio publishes genetic, health data in American Journal of Human Genetics
- BridgeBio initiated with a Buy at Truist
- These 2 Momentum Stocks Got a Bullish Nod — Here’s Why They Could Reach New Highs
- BridgeBio Pharma’s Promising Diversification and High-Margin Opportunities Drive Buy Rating
- Rivian downgraded, PayPal upgraded: Wall Street’s top analyst calls